|
1
|
Shirakawa R and Horiuchi H: Ral GTPases:
Crucial mediators of exocytosis and tumorigenesis. J Biochem.
157:285–299. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Moghadam AR, Patrad E, Tafsiri E, Peng W,
Fangman B, Pluard TJ, Accurso A, Salacz M, Shah K, Ricke B, et al:
Ral signaling pathway in health and cancer. Cancer Med.
6:2998–3013. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Schubbert S, Shannon K and Bollag G:
Hyperactive ras in developmental disorders and cancer. Nat Rev
Cancer. 7:295–308. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Guo TA, Wu YC, Tan C, Jin YT, Sheng WQ,
Cai SJ, Liu FQ and Xu Y: Clinicopathologic features and prognostic
value of KRAS, NRAS and BRAF mutations and DNA mismatch repair
status: A single-center retrospective study of 1,834 Chinese
patients with stage I-IV colorectal cancer. Int J Cancer.
15:1625–1634. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yan C and Theodorescu D: RAL GTPases:
Biology and potential as therapeutic targets in cancer. Pharmacol
Rev. 70:1–11. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Martin TD, Samuel JC, Routh ED, Der CJ and
Yeh JJ: Activation and involvement of ral GTPases in colorectal
cancer. Cancer Res. 71:206–215. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Oxford G, Owens CR, Titus BJ, Foreman TL,
Herlevsen MC, Smith SC and Theodorescu D: RalA and RalB:
Antagonistic relatives in cancer cell migration. Cancer Res.
65:7111–7120. 2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Smith SC, Baras AS, Owens CR, Dancik G and
Theodorescu D: Transcriptional signatures of ral GTPase are
associated with aggressive clinicopathologic characteristics in
human cancer. Cancer Res. 72:3480–3491. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ushigome M, Nabeya Y, Soda H, Takiguchi N,
Kuwajima A, Tagawa M, Matsushita K, Koike J, Funahashi K and
Shimada H: Multi-panel assay of serum autoantibodies in colorectal
cancer. Int J Clin Oncol. 23:917–923. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Takeda A, Shimada H, Nakajima K, Imaseki
H, Suzuki T, Asano T, Ochiai T and Isono K: Monitoring of p53
autoantibodies after resection of colorectal cancer: Relationship
to operative curability. Eur J Surg. 167:50–53. 2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Suzuki T, Shimada H, Ushigome M, Koike J,
Funahashi K, Nemoto T and Kaneko H: Three-year monitoring of serum
p53 antibody during chemotherapy and surgery for stage IV rectal
cancer. Clin J Gastroenterol. 9:55–58. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ushigome M, Shimada H, Miura Y, Yoshida K,
Kaneko T, Koda T, Nagashima Y, Suzuki T, Kagami S and Funahashi K:
Changing pattern of tumor markers in recurrent colorectal cancer
patients before surgery to recurrence: Serum p53 antibodies, CA19-9
and CEA. Int J Clin Oncol. 25:622–632. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nanami T, Shimada H, Yajima S, Oshima Y,
Matsushita K, Nomura F, Nagata M, Tagawa M, Otsuka S, Kuwajima A
and Kaneko H: Clinical significance of serum autoantibodies against
ras-like GTPases, RalA, in patients with esophageal squamous cell
carcinoma. Esophagus. 13:167–172. 2016.
|
|
14
|
Wang P, Qin J, Ye H, Li L, Wang X and
Zhang J: Using a panel of multiple tumor-associated antigens to
enhance the autoantibody detection in the immunodiagnosis of
ovarian cancer. J Cell Biochem. 120:3091–3100. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kubota Y, Ogata H, Otsuka S, Kuwajima A,
Saito F and Shimada H: Presence of autoantibodies against ras-like
GTPases in serum in stage I/II breast cancer. Toho J Med.
3:125–130. 2017.
|
|
16
|
Okada R, Otsuka Y, Wakabayashi T, Shinoda
M, Aoki T, Murakami M, Arizumi S, Yamamoto M, Aramaki O, Takayama
T, et al: Six autoantibodies as potential serum biomarkers of
hepatocellular carcinoma: A prospective multicenter study. Int J
Cancer. 23(1002)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nanami T, Hoshino I, Ito M, Yajima S,
Oshima Y, Suzuki T, Shiratori F, Nabeya Y, Funahashi K and Shimada
H: Prevalence of autoantibodies against ras-like GTPases, RalA, in
patients with gastric cancer. Mol Clin Oncol. 13(28)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A (eds): AJCC Cancer Staging Manual, 7th
edition. Springer, New York, NY, 2010.
|
|
19
|
Li Y, Karjalainen A, Koskinen H, Hemminki
K, Vainio H, Shnaidman M, Ying Z, Pukkala E and Brandt-Rauf PW: P53
autoantibodies predict subsequent development of cancer. Int J
Cancer. 114:157–160. 2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hoshino I, Nagata M, Takiguchi N, Nabeya
Y, Ikeda A, Yokoi S, Kuwajima A, Tagawa M, Matsushita K, Satoshi Y
and Hideaki S: Panel of autoantibodies against multiple
tumor-associated antigens for detecting gastric cancer. Cancer Sci.
108:308–315. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang JY, Casiano CA, Peng XX, Koziol JA,
Chan EL and Tan EM: Enhancement of antibody detection in cancer
using panel of recombinant tumor-associated antigens. Cancer
Epidemiol Biomarkers Prev. 12:136–143. 2003.PubMed/NCBI
|
|
22
|
Okada R, Shimada H, Tagawa M, Matsushita
K, Otsuka Y, Kuwajima A and Kaneko H: Profiling of serum
autoantibodies in Japanese patients with hepatocellular carcinoma.
Toho J Med. 3:84–92. 2017.
|
|
23
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tchevkina E, Agapova L, Dyakova N,
Martinjuk A, Komelkov A and Tatosyan A: The small G-protein RalA
stimulates metastasis of transformed cells. Oncogene. 24:329–335.
2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yan C, Liu D, Li L, Wempe MF, Guin S,
Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, et al:
Discovery and characterization of small molecules that target the
GTPase ral. Nature. 515:443–447. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shimada H, Okazumi S, Matsubara H,
Shiratori T, Akutsu Y, Nabeya Y, Tanizawa T, Matsushita K, Hayashi
H, Isono K and Ochiai T: Long-term results after dissection of
positive thoracic lymph nodes in patients with esophageal squamous
cell carcinoma. World J Surg. 32:255–261. 2008.PubMed/NCBI View Article : Google Scholar
|
